ExoEdit® for Rett Syndrome
Rett Syndrome
Pre-clinicalActive
Key Facts
About Evox Therapeutics
Evox Therapeutics is a private, pre-clinical stage biotech founded in 2016 and headquartered in Oxford, UK. The company is developing a novel therapeutic platform, ExoEdit®, which leverages engineered exosomes to deliver proprietary gene editors to the brain, aiming to address the root cause of genetically-driven neurodegenerative diseases. Its strategy involves building a pipeline based on human genetic data and preclinical validation while actively seeking strategic partnerships to advance its mission. Recent activities include a collaboration with the Rett Syndrome Research Trust and strengthening its governance with key board and advisory appointments.
View full company profileTherapeutic Areas
Other Rett Syndrome Drugs
| Drug | Company | Phase |
|---|---|---|
| RTT1 | Grann Pharmaceuticals | Pre-clinical |
| NEX-1 / NEX-2 | Nexien BioPharma | Pre-clinical / Phase 1 |
| KIT-13 | NeuroCores | Pre-clinical |
| DPM-1003 | DepYmed | Phase 1 |
| RVL-001 (vorinostat) | Unravel Biosciences | Clinical Trial Initiated |
| Rett Syndrome Program | Herophilus | Discovery |
| Glutamate Modulator for Rett Syndrome | Numedicus | Licensed/Orphan Designation |
| DAYBUE® (trofinetide) | Neuren Pharmaceuticals | Approved |
| TSHA-102 | Taysha Gene Therapies | Phase 1/2 |
| Sarizotan | Newron Pharmaceuticals | Phase III |
| NGN-401 | Neurogene | Phase 1/2 & Registrational |
| Blarcamesine (ANAVEX®2-73) | Anavex Life Sciences | Phase 2/3 |